Table 1 from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma
Abstract
Overview of response or T-cell clonality in clinically evaluable participants, RNA-seq–evaluable participants, and immunoSEQ-evaluable participants.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Hepatocellular Carcinoma Treatment and Prognosis
Hepatitis B Virus Studies
Publication details
- Publication date
- 17 February 2026
- Language
- EN